Navigation Links
Improving the potential of cancer vaccines

A special stretch of genetic material may turn off the immune suppression that stymies attempts to fight cancer with a vaccine, said researchers at Baylor College of Medicine (BCM) at Houston.

In a report in today's issue of the journal Science, Dr. Rong-Fu Wang, a professor in the BCM Center for Cell and Gene Therapy and Department of Immunology, and his colleagues describe a new strategy to turn off the function of a special group of T cells to suppress immune response to tumors and even infectious diseases.

"Since 1995, many groups have tried to develop a vaccine for the treatment of cancer," said Wang, also a member of the faculty of the BCM Graduate School of Biomedical Sciences. "The only problem is that after 10 years of clinical trials, the data suggest that you can induce (cancer) antigen-specific immune responses, but such responses are too weak and transient to eradicate tumor cells."

The answer lies in a group of cells called CD4+ regulatory T cells (Treg for short). These cells have the ability to suppress the body's natural immune response. If they are depleted, autoimmune diseases will result because the immune system is unchecked and goes on to attack the body's own tissues.

His group previously reported the existence of tumor-specific Treg cells at tumor sites. "Thus, the tumor cells use these Treg cells to protect themselves," said Wang. "In fact, tumor cells can actively recruit and activate them to turn on their immune suppressive function."

One way to stop this action is to simply wipe out the cells with chemoagents or a specific antibody.

"But you may also deplete the good cells needed for fighting cancer," said Wang.

He and his group identified particular ligands (a special stretch of guanosine-containing DNA material) that can bind specifically to a particular receptor called human Toll-like receptor 8 and then turn off the suppressive function of Treg cells.

Treatment of Treg ce lls with these ligands converts suppressive Treg cells into non-suppressive T cells.

"In fact, in some cases, this treatment actually enhanced anti-tumor immunity," he said.

He hopes that clinical trials with these special ligands in patients with cancer can get underway quickly.

"It could have a huge impact on cancer therapy or treatment of infectious disease," said Wang. "It could boost response to cancer vaccine as well."


'"/>

Source:Baylor College of Medicine


Related biology news :

1. Improving outcomes in premature births
2. MetaChip provides quick, efficient toxicity screening of potential drugs
3. Simple drug has the potential to save many lives threatened by malaria
4. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
5. Engineers improve plastics potential for use in implants by linking it to biological material
6. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
7. Snapin: A protein with therapy potential for autism
8. Slipping past the blood brain barrier: Research shows potential treatment for brain cancer
9. LIAI scientists make major finding on potential smallpox treatment
10. Neurotransmitters signal aggressive cancer, offer potential for early diagnosis
11. Researchers develop new testing methods for potential monkeypox or smallpox outbreak
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology: